| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Senior Vice President
1 company
Tim Ocain last filed a Form 4 in February 2019, as Senior Vice President at ENTA. Tim Ocain's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 17,547 shares of ENTA. The ENTA filings lean toward selling, a net 25,000 shares.
Tim Ocain has 9 Form 4 filings on record from November 2015 to February 2019, all as Senior Vice President at Enanta Pharmaceuticals (ENTA), 2015–2019.
The 20 reported transactions were 5 stock awards, 5 option or other derivative awards, 4 open-market sales and 3 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $2.1M.
The only open-market sale was 25,000 shares of ENTA at an average $83.64 on October 1, 2018, about $2.1M.
Shares as reported in the last Form 4 for each company; the most recent is from February 2019. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2018 | ENTA Enanta Pharmaceuticals Inc | Senior Vice President | Sale+OE | 25,000 | $83.64 | $2,090,903.40 | -80.3% |